

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

EHLICH *et al.*

Appl. No.: 10/594,177

Filed: August 13, 2007

For: **Secreted Proteins as Markers for  
Cell Differentiation**

Confirmation No.: 5698

Art Unit: 1633

Examiner: HIRIYANNA, Kelaginamane T.

Atty. Docket: 2590.0050002/EJH/PAC

**Second Supplemental Information Disclosure Statement**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on September 17, 2009 in connection with the above-captioned application.

Copies of documents **FP4-FP8** and **NPL17** are submitted. The documents were cited by a foreign patent office in a counterpart foreign application. Document **FP6**, is in the Japanese language. An English language equivalent of document FP6 is cited as document **FP5**. Document **FP7**, is in the Japanese language. An English language equivalent of document FP7 is cited as document **FP4**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.


This Information Disclosure Statement is being filed within three months of the date of filing of a national application other than a continued prosecution application (CPA), OR within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, OR before the mailing date of a first

Office Action on the merits OR before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Paul A. Calvo  
Attorney for Applicants  
Registration No. 57,913

Date: 7/26/10

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

1139829\_1.DOC